A Randomised, Open-Label, Comparative Study of Itraconazole vs Amphotericin B for the Induction Therapy of Penicilliosis. (360G-Wellcome-096471_Z_11_Z)
Penicilliosis is emerging as one of the three most common HIV-associated opportunistic infections in Asia.Despite the rapid growing HIV epidemics in a region that houses one half of the worlds population, there hasnot been a single randomised controlled trial to evaluate the treatment of penicilliosis. The currentrecommendation of amphotericin B for 2 weeks followed by itraconazole for 10 weeks is based on onenon-comparative study [1]. Amphotericin B has extremely limited availability, has significant side effects,needs to adminstered through a vein daily over 6 hours of infusion, and is prohibitively expensive in mostareas of Asia. Itraconazole, on the other hand, is widely available in local pharmacies throughout Asia, canbe given orally at a fraction of the price. Further, data from available case series suggest that itraconazoleand amphotericin B have similar efficacies. We therefore propose to conduct a randomised, open-label,non-inferiority trial of the efficacy of itraconazole versus amphotericin B for penicilliosis. 440 adults from inand outpatient settings with culture-confirmed penicilliosis will be recruited, randomly allocated to eitheritraconazole or amphotericin B treatment, monitored daily in-hospital for 2 weeks, and at monthly intervalsfor a total of 6 months. Primary outcome is mortality at 2 weeks. Secondary outcomes include 6-monthsurvival, clinical response, relapse, drug tolerability, and economic costs. Correlates of interests includeadmission prognostic factors, time-to-culture-sterilization, fungicidal activities, pharmacokinetic parameters,and serologic titres. These results will be available within five years and will either change or support currenttreatment guidelines for penicilliosis.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 305683 |
Applicant Surname | Le |
Approval Committee | Joint Global Health Trials Committee |
Award Date | 2011-05-16T00:00:00+00:00 |
Financial Year | 2010/11 |
Grant Programme: Title | Joint Global Health Trials Award |
Internal ID | 096471/Z/11/Z |
Lead Applicant | Dr Thuy Le |
Partnership Name | Joint Global Health Trials |
Partnership Value | 305683 |
Planned Dates: End Date | 2016-01-31T00:00:00+00:00 |
Planned Dates: Start Date | 2011-08-01T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | South East |